The mechanisms of vitamin K2-induced apoptosis of myeloma cells

Haematologica

Volumn 91, Issue 5, 2006, Pages 613-619

  Tsujioka, Takayuki ^a   Miura, Yoshie ^b   Otsuki, Takemi ^a   Nishimura, Yasumitsu ^a   Hyodoh, Fuminori ^a   Wada, Hideho ^a   Sugihara, Takashi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

Apoptosis; Myeloma vitamin K2; ROS mitochondria

Indexed keywords

ALLOPURINOL; BLOOD CLOTTING FACTOR; CASPASE 3; CASPASE 9; CYTOCHROME C; DEXAMETHASONE; FARNOQUINONE; GLUTAMIC ACID DERIVATIVE; GROWTH INHIBITOR; HYDROETHIDINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL X; PROTEIN BCL XL; PROTHROMBIN; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; XANTHINE;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CARBOXYLATION; CELL CULTURE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOMA CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MYELOMA CELL; PHOSPHORYLATION; PROTEIN EXPRESSION; TUMOR CELL; WESTERN BLOTTING;

ALLOPURINOL; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CASPASES; CELL DIVISION; CELL LINE, TUMOR; DEXAMETHASONE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HUMANS; LYMPHOMA, B-CELL; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE OXYGEN SPECIES; SUPEROXIDES; VITAMIN K 2;

EID: 33744495081     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Mitsiades CS, Mitsiades N, Munshi NC, Andersen KC. Focus on multiple myeloma. Cancer Cell 2004;6:439-44.
2. Wiernik PH. Plasma cell myeloma and leukemia. Cancer Chemother Biol Response Modif 2003;21:365-97.
3. Sirohi B, Powles R. Multiple myeloma. Lancet 2004;363:875-87.
4. Shapiro-Shelef M, Calame K. Plasma cell differentiation and multiple myeloma. Curr Opin Immunol 2004;16:226-34.
5. Pratt G. Molecular aspects of multiple myeloma. Mol Pathol 2002;55:273-83.
6. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
7. Abedi M, Elfenbein GJ. Novel approaches in the treatment of multiple myeloma. Med Health R I 2003;86:231-5.
8. Pichardo D, Singhal S, Mehta J, Rosen S. Recent developments and future directions in the treatment of multiple myeloma. Cancer Biother Radiopharm 2003;18:497-511.
9. Clerc D, Fermand JP, Mariette X. Treatment of multiple myeloma. Joint Bone Spine 2003;70:175-86.
10. Kaufman J, Lonial S. Multiple myeloma: the role of transplant and novel treatment strategies. Semin Oncol 2004;31:99-105.
11. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18.
12. Barille-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, et al. Advances in biology and therapy of multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2003;248-78.
13. Harousseau JL. Management of multiple myeloma. Rev Clin Exp Hematol 2002;6:253-75.
14. Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2002;214-40.
15. Moehler TM, Hillengass J, Goldschmidt H, Ho AD. Antiangiogenic therapy in hematologic malignancies. Curr Pharm Des 2004;10:1221-34.
16. Weber D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 2003;10:375-83.
17. Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. J Cell Mol Med 2002;6:160-74.
18. Colson K, Doss DS, Swift R, Tariman J, Thomas TE. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs 2004;8:473-80.
19. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361-9.
20. Adams J. Development of the proteasome inhibitor PS-341. The Oncologist 2002;7:9-16.
21. Meganathan R. Biosynthesis of menaquinone (vitamin K2) and ubiquinone (coenzyme Q): a perspective on enzymatic mechanisms. Vitam Horm 2001;61:173-218.
22. Newman P, Shearer MJ. Vitamin K metabolism. Subcell Biochem 1998;30:455-88.
23. Uotila L. The metabolic functions and mechanism of action of vitamin K. Scand J Clin Lab Invest Suppl 1990;201:109-17.
24. Olson RE. The function and metabolism of vitamin K. Annu Rev Nutr 1984;4:281-337.
25. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. The Warfarin Reversal Consensus Group. Med J Aust 2004;181:492-7.
26. Sutor AH. New aspects of vitamin K prophylaxis. Semin Thromb Hemost 2003;29:373-6.
27. Butenas S, Mann KG. Blood coagulation. Biochemistry 2002;67:3-12.
28. Yokoyama T, Miyazawa K, Yoshida T, Ohyashiki K. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines. Int J Oncol 2005;26:33-40.
29. Oztopcu P, Kabadere S, Mercangoz A, Uyar R. Comparison of vitamins K1, K2 and K3 effects on growth of rat glioma and human glioblastoma multiforme cells in vitro. Acta Neurol Belg 2004;104:106-10.
30. Otsuka M, Kato N, Shao RX, Hoshida Y, Ijichi H, Koike Y, et al. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004;40:243-51.
31. Lamson DW, Plaza SM. The anticancer effects of vitamin K. Altern Med Rev 2003;8:303-18.
32. Okayasu H, Ishihara M, Satoh K, Sakagami H. Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines. Anticancer Res 2001;21:2387-92.
33. Miyazawa K, Nishimaki J, Ohyashiki K, Enomoto S, Kuriya S, Fukuda R, et al. Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan. Leukemia 2000;14:1156-7.
34. Nishimaki J, Miyazawa K, Yaguchi M, Katagiri T, Kawanishi Y, Toyama K, et al. Vitamin K2 induces apoptosis of a novel cell line established from a patient with myelodysplastic syndrome in biastic transformation. Leukemia 1999;13:1399-405.
35. Yaguchi M, Miyazawa K, Otawa M, Katagiri T, Nishimaki J, Uchida Y, et al. Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody. Leukemia 1998;12:1392-7.
36. Miyazawa K, Yaguchi M, Funato K, Gotoh A, Kawanishi Y, Nishizawa Y, et al. Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia 2001;15:1111-7.
37. Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004;10:125-9.
38. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004;23:2838-49.
39. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-2.
40. Otsuki T, Yata K, Takata-Tomokuni A, Hyodoh F, Miura Y, Sakaguchi H, et al. Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. Br J Haematol 2004;127:292-8.
41. Otsuki T, Yata K, Sakaguchi H, Kurebayashi J, Matsuo Y, Uno M, et al. Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells. Br J Haematol 2002;116:787-95.
42. Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisue H, et al. Estrogen receptors in human myeloma cells. Cancer Res 2000;60:1434-41.
43. Walrand S, Valeix S, Rodriguez C, Ligot P, Chassagne J, Vasson MP. Flow cytometry study of polymorphonuclear neutrophil oxidative burst: a comparison of three fluorescent probes. Clin Chim Acta 2003;331:103-10.
44. Filatov MV, Varfolomeeva E Y, Ivanov EI. Flow cytofluorometric detection of inflammatory processes by measuring respiratory burst reaction of peripheral blood neutrophils. Biochem Mol Med 1995;55:116-21.
45. Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem 2002;9:195-217.
46. Lacombe F, Belloc F. Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Hematol Cell Ther 1996;38:495-504.
47. Uematsu T, Nagashima S, Niwa M, Kohno K, Sassa T, Ishii M, et al. Effect of dietary fat content on oral bioavailability of menatetrenone in humans. J Pharm Sci 1996;85:1012-6.
48. Miki T, Nakatsuka K, Naka H, Kitatani K, Saito S, Masaki H, et al. Vitamin K(2) (menaquinone 4) reduces serum under-carboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis. J Bone Miner Metabol 2003;21:161-5.
49. Sato M, Crasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
50. Takami A, Asakura H, Nakao S. Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome. Ann Hematol 2002;81:16-9.
51. Takami A, Nakao S, Ontachi Y, Yamauchi H, Matsuda T. Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol 1999;69:24-6.
52. Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004;117:508-15.
53. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol 2003;1:194-205.
54. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611-22.
55. Chesi M, Kuehl WM, Bergsagel PL. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann Oncol 2000;11S1:131-5.
56. Raje N, Anderson KC. Introduction: the evolving role of bisphosphonate therapy in multiple myeloma. Blood 2000;96:381-3.
57. Grander D. How does interferon-α exert its antitumour activity in multiple myeloma? Acta Oncol 2000;39:801-5.